Form 4 for VNDA Vanda Pharmaceuticals Inc.
Accepted 2022-06-21 00:00:00 ET · period of report 2022-06-16 · accession 0001209191-22-038449 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2022-06-21 | 2022-06-16 | VNDA | Ward Anne Sempowski | Dir | A - Grant | $0.00 | +12.0K | 22.0K | +120% | $0 |
| D | 2022-06-21 | 2022-06-16 | VNDA | Ward Anne Sempowski | Dir | A - Grant | $0.00 | +24.7K | 24.7K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-06-16 | A | A | 12,006 | $0.00 | 22,006 | D | — | — | (F1) Represents shares of common stock underlying a time-based restricted stock unit award (RSU). 100% of the shares subject to this RSU will vest on June 16, 2023, provided that the Reporting Person has provided continuous service to the Issuer through the vesting date. |
| 2 | Derivative | Stock Option (right to buy) | 2022-06-16 | A | A | 24,707 | $0.00 | 24,707 | D | $9.37 · — to 2032-06-15 | 24,707 Common Stock | (F2) This option vests and becomes exercisable with respect to 100% of the option shares on June 16, 2023, provided that the Reporting Person has provided continuous service to the Issuer through the vesting date. |